The Invention Lab (CEO Jinyoung Kim) announced on the 26th that it has executed new and follow-up investments in three startups (Motion Labs, Urban Data Lab, and Neuroen) that are growing based on innovative technologies in the bio and healthcare fields.
The first investment target, Motion Labs, is a company that provides patient management service ‘Revisit’ and hospital content automation system through data and AI-based medtech solutions. It has already secured more than 240 paying hospital customers through content-based CRM delivery tailored to the treatment cycle and multilingual health checkup management solution, and continues to operate in the black.
The Invention Lab made an initial investment through Boryeong DHealth Discovery Joint Stock Company No. 1, which was established through the Boryeong and Open Innovation Program in 2020, and made a follow-up investment of over KRW 1.5 billion by establishing a joint fund with medical experts who actually use Revizit. In the future, Motion Labs plans to focus on advancing into Southeast Asia, including Vietnam and Indonesia, and developing AI-based hospital-specific agents.
The second investment, Urban Data Lab, is developing a SaaS-type digital pathology solution that can utilize large-scale tissue cell image data in a cloud environment. It is advancing AI technology that assists in cancer diagnosis based on in-hospital pathology data based on a dataset built with upper-level general hospitals, and The Invention Lab invested through Digital Innovation 2030 Private Investment Association No. 4, which is comprised of former Samsung Group executives. Urban Data Lab is also promoting the recommendation of the Deep Tech Tips program in the second half of the year.
Lastly, Neuroen is a startup that develops brain function-based mental illness diagnosis and customized treatment solutions, and is led by CEO Oh Do-yeon, who is from LG Electronics, and Easybrain Director Lee Jae-won, a psychiatrist and doctor of brain engineering. Neuroen is implementing a clinician-centered treatment system that integrates patient consultation, prescription, and brain function test data to suggest neuromodulation and drug treatment for various mental illnesses such as PTSD, autism, and depression based on AI.
The Invention Lab CEO Jinyoung Kim said, “We have high expectations for startups in the bio and healthcare fields that are creating solid customer indicators and have global scalability based on technological competitiveness,” adding, “We will strengthen close support from initial investment to actual follow-up growth.”
- See more related articles
You must be logged in to post a comment.